Caladrius Biosciences Inc. (CLBS)
0.43
-0.08 (-16.05%)
Sep 15, 2022, 4:00 AM - Market open
-16.05% (1D)
| Bid | n/a |
| Market Cap | 3.35M |
| Revenue (ttm) | 125.59M |
| Net Income (ttm) | -24.57M |
| EPS (ttm) | -0.394 |
| PE Ratio (ttm) | -1.0822335025380712 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 26,946,654 |
| Avg. Volume (20D) | undefined |
| Open | 0.65 |
| Previous Close | 0.51 |
| Day's Range | 0.38 - 0.65 |
| 52-Week Range | undefined - undefined |
| Beta | 0.91 |
About CLBS
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysf...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 3, 1995
Employees 27
Stock Exchange NASDAQ
Ticker Symbol CLBS
Website https://www.caladrius.com